Acute Leukemia Clinical Trial
Official title:
A Randomized Pilot Trial Comparing Anti-Thymocyte Globulin (ATG) With ATG Plus Post Transplant Cyclophosphamide (PTCy) for Prophylaxis Against Acute and Chronic Graft Versus Host Disease (GVHD)
A Randomized Pilot Trial to test the feasibility of comparing anti-thymocyte globulin plus post transplant cyclophosphamide with anti-thymocyte globulin alone to prevent chronic graft versus host disease.
Status | Recruiting |
Enrollment | 80 |
Est. completion date | December 31, 2024 |
Est. primary completion date | October 13, 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 16 Years to 70 Years |
Eligibility | Inclusion Criteria: 1. The participant is aged = 16 and deemed medically fit per investigator for protocol 2. The participant has either acute myeloid leukemia in 1st or 2nd complete remission (CR), or has myelodysplastic syndrome 3. The participant will receive a blood progenitor cell graft ("HPC, Apheresis") 4. The participant has a related or unrelated donor, who is fully MHC matched with the recipient at HLA-A, B, C and DRB1. 5. The participant meets the transplant centre's criteria for transplantation, using either myeloablative or reduced intensity conditioning. 6. The participant has good performance status (Karnofsky =60%) 7. The participant is able to understand and sign the informed consent form 8. Ability and willingness to comply with study procedures and schedule, in the Investigator's opinion. 9. The participant is receiving their first transplant Exclusion Criteria: 1. The participant is HIV antibody positive 2. The participant has a hypersensitivity to rabbit proteins or Thymoglobulin® pharmaceutical excipients, glycine or mannitol. 3. The participant has active or chronic infection (i.e. infection requiring oral or IV therapy) 4. The participant (if female and of childbearing potential) is pregnant or breast-feeding at the time of enrollment 5. The participant (if female and of childbearing potential) does not agree to use an adequate contraceptive method from the time of enrollment until a minimum of one year following transplant3 6. The participant (if male and fertile) does not agree to use an adequate contraceptive method from the time of enrollment until a minimum of one year following transplant3 7. The participant has urinary outflow obstruction 8. The participant is in poor condition (determined per institutional guidelines) 9. The participant has acute leukemia in relapse 10. The participant has myelodysplastic syndrome with > 10% marrow blasts 11. The participant is having their second transplant 12. The participant is taking T-cell antibody prophylaxis (anti-CD52) 13. The participant is receiving a cord blood graft or T-cell depleted grafts 14. The participant has mixed phenotype acute leukemia 15. The participant has prior malignancies, except resected nonmelanoma or treated cervical carcinoma in situ. Cancer treated with curative intent = 5 years previously will be allowed. Cancer treated with curative intent < 5 years previously must be reviewed and approved by the sponsors. 16. The participant is in complete remission with incomplete recovery (CRi) |
Country | Name | City | State |
---|---|---|---|
Australia | Kinghorn Cancer Centre, St Vincent's Health Network | Darlinghurst | New South Wales |
Australia | Australasian Leukaemia and Lymphoma Group | Melbourne | Victoria |
Australia | Royal North Shore Hospital | St. Leonards | New South Wales |
Canada | Queen Elizabeth II Health Sciences Centre | Halifax | Nova Scotia |
Canada | Juravinski Hospital and Cancer Centre | Hamilton | Ontario |
Canada | London Health Sciences Centre | London | Ontario |
Canada | Hôpital de l'Enfant-Jésus | Québec City | Quebec |
Canada | Saskatchewan Cancer Agency | Saskatoon | Saskatchewan |
Canada | CancerCare Manitoba | Winnipeg | Manitoba |
Lead Sponsor | Collaborator |
---|---|
McMaster University | Cell Therapy Transplant Canada, Ozmosis Research Inc., Sanofi |
Australia, Canada,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Registration of 80 patients within twenty four months | Registration will be documented by the Clinical Research Organization (Ozmosis Research Inc.) | 24 months | |
Secondary | CRFS | Chronic graft versus host disease free- and relapse-free survival (CRFS) | 27 months | |
Secondary | GRFS | Graft versus host disease-, and relapse-, free survival (GRFS) | 27 months | |
Secondary | Survival | Survival (dead/alive) at 100 days for each patient | 27 months | |
Secondary | Complete data collection | The Clinical Research Organization (Ozmosis Research Inc.) will document completeness of data collection | 27 months | |
Secondary | Cost of study | The sponsor (McMaster University) and the Clinical Research Organization (Ozmosis Research Inc.) will compare actual total trial costs in Canadian dollars at trial completion (at completion of outcomes analysis and report) with expected costs as determined for the trial budget. | 27 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05088356 -
Reduced Intensity Allogeneic HCT in Advanced Hematologic Malignancies w/T-Cell Depleted Graft
|
Phase 1 | |
Recruiting |
NCT04904588 -
HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide
|
Phase 2 | |
Recruiting |
NCT04969601 -
Anti-Covid-19 Vaccine in Children With Acute Leukemia and Their Siblings
|
Phase 1/Phase 2 | |
Recruiting |
NCT02356159 -
Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation
|
Phase 1/Phase 2 | |
Withdrawn |
NCT05170828 -
Cryopreserved MMUD BM With PTCy for Hematologic Malignancies
|
Phase 1 | |
Terminated |
NCT02877082 -
Tacrolimus, Bortezomib, & Thymoglobulin in Preventing Low Toxicity GVHD in Donor Blood Stem Cell Transplant Patients
|
Phase 2 | |
Active, not recruiting |
NCT01956630 -
Clinical Study of DC Plus CIK for Patients With Relapse Acute Leukemia After Allo-HSCT
|
Phase 1/Phase 2 | |
Completed |
NCT00988013 -
Intensity Modulated Total Marrow Irradiation (IM-TMI) for Advanced Hematologic Malignancies
|
N/A | |
Enrolling by invitation |
NCT01728402 -
Pathogenesis of Hematologic Malignancies
|
||
Active, not recruiting |
NCT03595800 -
Extension of a Study of Allogeneic Hematopoietic Stem Cell Transplantation From One Haplotype Mismatch Related Donor or From an Unrelated Donor to Younger Patients Eligible for Reduced-intensity Conditioning Regimen
|
Phase 3 | |
Completed |
NCT02440178 -
Micafungin Prophylaxis During 1st Induction Chemotherapy for De Novo Acute Leukemia
|
Phase 2 | |
Recruiting |
NCT05071482 -
Flumatinib Versus Imatinib Combined With Chemotherapy for de Novo Ph+ ALL
|
Phase 4 | |
Withdrawn |
NCT03138395 -
iCare3: Monitoring Circulating Cancer DNA After Chemotherapy in MDS and AML
|
N/A | |
Completed |
NCT03042676 -
Electronic Database for the Follow up of the ATG_FamilyStudy
|
||
Completed |
NCT04597086 -
Bright White Light Therapy for the Improvement of Sleep, Fatigue, Distress, Depression, and Anxiety in Hospitalized Leukemia Patients
|
N/A | |
Terminated |
NCT03588936 -
Nivolumab and Tocilizumab for Relapsed Hematological Malignancy Post-allogeneic Transplant
|
Phase 1 | |
Recruiting |
NCT05521204 -
Olverembatinib for FGFR1-rearranged Neoplasms
|
Phase 2 | |
Not yet recruiting |
NCT04084327 -
Immunophenotyping of Acute b Cell Lymphoblstic Leukemia
|
||
Terminated |
NCT00852709 -
Phase I Dose-Escalation Trial of Clofarabine Followed by Escalating Doses of Fractionated Cyclophosphamide in Children With Relapsed or Refractory Acute Leukemias
|
Phase 1 | |
Not yet recruiting |
NCT06026839 -
Longitudinal Study on the QoL of Pediatric Patients After HSCT and Its Influencing Factors
|